<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 11:30 - 11:35 | Welcome and introduction  
S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH |
| 11:35 - 11:50 | KRASG12C inhibition: A major landmark in 2nd line treatment of patients with advanced NSCLC  
J. De Langen, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL |
| 11:50 - 12:05 | The turning point: Practical considerations when emerging biomarkers become actionable  
K. Kerr, Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB |
| 12:05 - 12:20 | Forward thinking: Future perspectives in targeting KRAS in NSCLC  
S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH |
| 12:20 - 12:35 | Panel discussion - Managing patients with KRAS $G12C$-mutant NSCLC: Real-world perspectives  
A. Speakers, CH |
| 12:35 - 12:55 | Audience Q&A  
A. Speakers, CH |
| 12:55 - 13:00 | Summary and close  
S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH |
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:30 - 11:50</td>
<td>The evolving landscape of advanced NSCLC therapy</td>
<td>R. Juergens, JCC - Juravinski Cancer Centre - Hamilton Health Sciences, Hamilton, CA</td>
</tr>
<tr>
<td>11:50 - 11:55</td>
<td>Welcome and introductions</td>
<td>M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE</td>
</tr>
<tr>
<td>11:55 - 12:15</td>
<td>Addressing resistance to checkpoint inhibitors in NSCLC</td>
<td>F. Cappuzzo, IRCCS Istiuto Nazionale Tumori Regina Elena (IRE), Rome, IT</td>
</tr>
<tr>
<td>12:15 - 12:35</td>
<td>Targeting KRAS-driven NSCLC</td>
<td>M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE</td>
</tr>
<tr>
<td>12:35 - 13:00</td>
<td>Q&amp;A;A and summary</td>
<td>A. Speakers, , CH</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session Description</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>13:30 - 14:15</td>
<td>Welcome to ELCC 2022 and Presentations of Heine H. Hansen Awards</td>
<td>F. Blackhall¹, J. Vansteenkiste², ¹Manchester, GB, ²Leuven, BE</td>
</tr>
<tr>
<td></td>
<td>Congress Hall</td>
<td></td>
</tr>
<tr>
<td>13:30 - 13:40</td>
<td>Presentation of Heine H. Hansen Awards 2020 and 2021</td>
<td></td>
</tr>
<tr>
<td>13:40 - 13:45</td>
<td>Introduction to the Heine H. Hansen Award 2022</td>
<td></td>
</tr>
<tr>
<td>13:45 - 14:10</td>
<td>Heine H. Hansen 2022 Keynote lecture</td>
<td></td>
</tr>
</tbody>
</table>
14:30 - 16:00  Implementation of screening programmes in Europe

South Hall 2

Moderation: T.B. Announced, , US

14:30 - 14:50  Where do we stand?
M. Oudkerk, University of Groningen, Groningen, NL

14:50 - 15:10  Reading guidelines
N. Bogot, Shaare Zedek Medical Center, Jerusalem, IL

15:10 - 15:30  Nodule investigation
D.R. Baldwin, City Hospital Campus - Nottingham University Hospitals NHS Trust, Nottingham, GB

15:30 - 15:50  Biomarkers in screening effort
L. Montuenga, Clinica Universidad de Navarra, Pamplona, ES

15:50 - 16:00  Q&A
A. Speakers, , CH

14:30 - 16:00  What to do after immunotherapy failure and when to avoid immunotherapy in early disease NSCLC

Congress Hall

Moderation: R.S. Herbst, Yale University School of Medicine, New heaven, US

14:30 - 14:45  What is the role of chemotherapy and antiangiogenics?
R.S. Herbst, Yale University School of Medicine, New heaven, US

14:45 - 14:55  Case presentation

14:55 - 15:10  IO rechallenge
B. Piet, Radboud University Medical Center, Nijmegen, NL

15:10 - 15:25  Novel approaches
J. Zugazagoitia, Hospital Universitario 12 de Octubre, Madrid, ES

15:25 - 15:40  When to avoid immunotherapy in early disease

15:40 - 16:00  Discussion
A. Speakers, , CH
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 - 16:00</td>
<td><strong>Not so small anymore: New therapies and cutting-edge science to guide the care of patients with small cell lung cancer</strong>&lt;br&gt;Moderation: J. Naidoo, Beaumont Hospital, Dublin, IE</td>
</tr>
<tr>
<td>14:30 - 14:50</td>
<td><strong>First shot on goal is the most important: Updates on first line therapy for limited stage and extensive stage SCLC</strong>&lt;br&gt;J. Naidoo, Beaumont Hospital, Dublin, IE</td>
</tr>
<tr>
<td>14:50 - 15:10</td>
<td><strong>Battling recurrent SCLC: Emerging therapies for platinum refractory disease</strong>&lt;br&gt;Lo Russo, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, IT</td>
</tr>
<tr>
<td>15:10 - 15:30</td>
<td><strong>Delivering on the promise of precision medicine in SCLC: Emerging molecular sub-types</strong>&lt;br&gt;Drapkin, UT Southwestern Medical Center, Dallas, US</td>
</tr>
<tr>
<td>15:30 - 15:50</td>
<td><strong>Transformed SCLC: Emerging science on histologic subtype switching</strong>&lt;br&gt;Sen, Memorial Sloan Kettering Cancer Center, New York, US</td>
</tr>
<tr>
<td>15:50 - 16:00</td>
<td><strong>Q&amp;A</strong>&lt;br&gt;Speakers, CH</td>
</tr>
<tr>
<td>16:30 - 18:00</td>
<td><strong>New insights in the treatment of geriatric patients</strong>&lt;br&gt;Moderation: Decoster, UZ Brussel - Universitair Ziekenhuis Brussel, Jette, BE</td>
</tr>
<tr>
<td>16:30 - 16:50</td>
<td><strong>Geriatric assessment in the chest MDT</strong>&lt;br&gt;Decoster, UZ Brussel - Universitair Ziekenhuis Brussel, Jette, BE</td>
</tr>
<tr>
<td>16:50 - 17:10</td>
<td><strong>Biological hallmarks of ageing: Potential therapeutic targets?</strong>&lt;br&gt;Ferrara, Fondazione IRCCS - Istituto Nazionale dei Tumori, Milan, IT</td>
</tr>
<tr>
<td>17:10 - 17:30</td>
<td><strong>Can AI help guide diagnosis and treatment of special cancer populations such as the elderly?</strong>&lt;br&gt;Dekker, Mastro Clinic, Maastricht, NL</td>
</tr>
<tr>
<td>17:30 - 17:50</td>
<td><strong>What past and future trials tell us</strong>&lt;br&gt;Corre, CH de Cornouaille - Hopital Laennec, Quimper, FR</td>
</tr>
<tr>
<td>17:50 - 18:00</td>
<td><strong>Q&amp;A</strong>&lt;br&gt;Speakers, CH</td>
</tr>
</tbody>
</table>
16:30 - 18:00  Thymic tumours  Congress Hall

Moderation: E. Ruffini¹, N. Girard², ¹University of Turin, Torino, IT, ²Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France; UVSQ, Paris Saclay Campus, Versailles, FR

16:30 - 16:50  Update on the Staging Project for the 9th edition of the TNM staging system of thymic tumors
E. Ruffini, University of Turin, Torino, IT

16:50 - 17:10  Early-stage tumors: What is the optimal surgical management in 2022?
V. Fang, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, CN

17:10 - 17:30  Locally advanced tumors: The key word is multidisciplinarity
A. Rimner, Memorial Sloan Kettering Cancer Center, New York, US

17:30 - 17:40  Q&A
A. Speakers, , CH

17:40 - 18:00  Advanced tumors, new frontiers: Promising results?
N. Girard, Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France; UVSQ, Paris Saclay Campus, Versailles, FR
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:15 - 18:20</td>
<td>Welcome and introduction</td>
<td>M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE</td>
</tr>
<tr>
<td>18:20 - 18:35</td>
<td>Precision medicine in NSCLC: From biomarker testing to therapy selection</td>
<td>M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE</td>
</tr>
<tr>
<td>18:35 - 19:00</td>
<td>Emerging therapies for advanced NSCLC With EGFR Exon 20 insertion mutations: Developments and implications</td>
<td>M. Perol, Centre Léon Bérard, Lyon, FR</td>
</tr>
<tr>
<td>19:25 - 19:43</td>
<td>Live Q&amp;A / discussion</td>
<td>A. Speakers, CH</td>
</tr>
<tr>
<td>19:43 - 19:45</td>
<td>Concluding remarks</td>
<td>M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE</td>
</tr>
</tbody>
</table>

Last update: 24-02-2022 02:14:04pm
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker</th>
<th>Institution</th>
<th>City</th>
<th>Country</th>
</tr>
</thead>
<tbody>
<tr>
<td>18:15 - 19:18</td>
<td>Welcome &amp; introductions</td>
<td>A. Scherpereel</td>
<td>DRC / CHRU of Lille</td>
<td>Lille</td>
<td>FR</td>
</tr>
<tr>
<td>18:18 - 18:38</td>
<td>The shifting treatment paradigm with I-O in resectable NSCLC</td>
<td>P. Forde</td>
<td>Johns Hopkins University</td>
<td>Baltimore</td>
<td>US</td>
</tr>
<tr>
<td>18:45 - 19:10</td>
<td>Understanding the potential for long-term survival with I-O in metastatic NSCLC</td>
<td>N. Reinmuth</td>
<td>Asklepios Lung Clinic</td>
<td>Munich-Gauting</td>
<td>DE</td>
</tr>
<tr>
<td>19:10 - 19:25</td>
<td>Closing remarks &amp; live Q&amp;A</td>
<td>A. Scherpereel</td>
<td>DRC / CHRU of Lille</td>
<td>Lille</td>
<td>FR</td>
</tr>
<tr>
<td>19:25 - 19:45</td>
<td>I-O as a new standard for patients with unresectable MPM</td>
<td>A. Scherpereel</td>
<td>DRC / CHRU of Lille</td>
<td>Lille</td>
<td>FR</td>
</tr>
<tr>
<td>19:45 - 20:00</td>
<td>Closing remarks &amp; live Q&amp;A</td>
<td>A. Scherpereel</td>
<td>DRC / CHRU of Lille</td>
<td>Lille</td>
<td>FR</td>
</tr>
</tbody>
</table>
### 31.03.2022

#### 08:00 - 09:00  Oligoprogession in advanced NSCLC  
**Congress Hall**  
Moderation: F. Mcdonald, Royal Marsden Hospital NHS Foundation Trust, London, GB

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:15</td>
<td><strong>Case presentation: Defining oligoprogession</strong></td>
</tr>
<tr>
<td></td>
<td>M. Guckenberger, Universitätsspital Zürich, Zürich, CH</td>
</tr>
<tr>
<td>08:15 - 08:30</td>
<td><strong>Is there a role for SBRT in oligoprogession?</strong></td>
</tr>
<tr>
<td></td>
<td>F. Mcdonald, Royal Marsden Hospital NHS Foundation Trust, London, GB</td>
</tr>
<tr>
<td>08:30 - 08:45</td>
<td><strong>Is there biological rationale for local approaches in oligoproggressive systemic disease?</strong></td>
</tr>
<tr>
<td></td>
<td>L. Sequist, Massachusetts General Hospital, Boston, US</td>
</tr>
<tr>
<td>08:45 - 09:00</td>
<td><strong>Discussion</strong></td>
</tr>
<tr>
<td></td>
<td>A. Speakers, CH</td>
</tr>
</tbody>
</table>

#### 08:00 - 09:00  Surgery vs radiation therapy for stage III NSCLC in the context of immunotherapy  
**Forum Hall**  
Moderation: K. Oselin, North Estonia Medical Centre Foundation (SA Pohja-Eesti Regionaalhaigla), Tallinn, EE

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:00 - 08:10</td>
<td><strong>Introduction and first vote</strong></td>
</tr>
<tr>
<td></td>
<td>K. Oselin, North Estonia Medical Centre Foundation (SA Pohja-Eesti Regionaalhaigla), Tallinn, EE</td>
</tr>
<tr>
<td>08:10 - 08:30</td>
<td><strong>Surgical perspective on neoadjuvant immunotherapy for resectable stage III non-small cell lung cancer</strong></td>
</tr>
<tr>
<td></td>
<td>A. Brunelli, St. James's University Hospital, Leeds, GB</td>
</tr>
<tr>
<td>08:30 - 08:50</td>
<td><strong>Radiotherapy perspective for resectable stage III non-small cell lung cancer in the era of immunotherapy</strong></td>
</tr>
<tr>
<td></td>
<td>C. Faivre-Finn, The Christie NHS Foundation Trust, Manchester, GB</td>
</tr>
<tr>
<td>08:50 - 09:00</td>
<td><strong>Second vote and conclusions</strong></td>
</tr>
<tr>
<td></td>
<td>K. Oselin, North Estonia Medical Centre Foundation (SA Pohja-Eesti Regionaalhaigla), Tallinn, EE</td>
</tr>
</tbody>
</table>

#### 08:00 - 09:00  YO session 1  
**South Hall 2**  
Moderation: T.B. Announced, US

---

Last update: 24-02-2022 02:14:04pm
09:15 - 09:25  **Introduction**  
F. Blackhall, Manchester, GB

09:25 - 09:45  **Tissue testing for actionable biomarkers in patients with advanced NSCLC: Scientific and implementation perspectives and the positioning of molecular tumour boards**  
F. Lopez-Rios, Hospital Universitario 12 de Octubre, Madrid, ES

09:45 - 10:05  **An overview of molecular epidemiology of rare molecular aberrations and matching treatment strategies for patients with non-EGFR, oncogene-addicted advanced NSCLC**  
F. Barlesi, Gustave Roussy - Cancer Campus, Villejuif, FR

10:05 - 10:20  **Live Q&A / discussion**  
A. Speakers, CH

10:20 - 10:40  **RET-fused NSCLC: State of the art treatment of advanced disease, including sanctuary sites**  
M. Garassino, University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US

10:40 - 10:45  **Concluding remarks**  
F. Lopez-Rios, Hospital Universitario 12 de Octubre, Madrid, ES
09:15 - 10:45  Minimal residual disease, biological disease
Moderation: C. Rolfo, New York, US

09:15 - 09:35  How MRD correlates with imaging in NSCLC?
F. Grossi, University of Insubria, Busto Arsizio, IT

09:35 - 09:55  How to assess MRD in NSCLC?
C. Rolfo, New York, US

09:55 - 10:15  MRD as a predictor of survival in NSCLC
P. Hofman, CHU Nice - Hopital Pasteur, Nice, FR

10:15 - 10:35  How to design clinical trials integrating MRD?
S. Gadgeel, Henry Ford Cancer Institute - Henry Ford Hospital, Detroit, US

10:35 - 10:45  Q&A

09:15 - 10:45  Telemedicine in lung cancer: What to do in 2022?
Moderation: N. Leighl, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

09:15 - 09:35  Improving outcome through electronic surveillance
F. Denis, ILC Jean Bernard, Le Mans, FR

09:35 - 09:55  Telescreening, here we come!
N. Leighl, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA

09:55 - 10:15  Applications of telehealth in lung cancer
A. Sivanandan, Nottingham, GB

10:15 - 10:35  Improving clinical trials reporting through telemedicine
L. Coate, University Hospital Limerick, Limerick, IE

10:35 - 10:45  Q&A
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:15</td>
<td><strong>First line in non-oncogene addicted</strong></td>
<td>Forum Hall</td>
<td>Moderation: J. Feliciano, Johns Hopkins Hospital, Baltimore, US</td>
</tr>
<tr>
<td>11:15</td>
<td>Biomarker testing (tissue, blood) for non-oncogenic addicted NSCLC</td>
<td></td>
<td>T. Stinchcombe, Duke Cancer Center, Durham, US</td>
</tr>
<tr>
<td>11:35</td>
<td><strong>First line therapy in non-oncogene addicted NSCLC</strong></td>
<td></td>
<td>M. Perol, Centre Léon Bérard, Lyon, FR</td>
</tr>
<tr>
<td>11:55</td>
<td>Long term needs and survivorship needs in advanced NSCLC</td>
<td></td>
<td>J. Feliciano, Johns Hopkins Hospital, Baltimore, US</td>
</tr>
<tr>
<td>12:15</td>
<td>Resistance to therapy in non-oncogene addicted NSCLC</td>
<td></td>
<td>S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH</td>
</tr>
<tr>
<td>12:35</td>
<td>Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15</td>
<td><strong>More targets, more drugs, more choices, more conflicts</strong></td>
<td>South Hall 2</td>
<td>Moderation: K. Kerr, Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB</td>
</tr>
<tr>
<td>11:15</td>
<td>Case presentation - A patient with ALK+ NSCLC: How clinical characteristics, biopsy specimen and cfDNA can guide treatment decisions</td>
<td></td>
<td>L. Mezquita, Hospital Clinic y Provincial de Barcelona, Barcelona, ES</td>
</tr>
<tr>
<td>11:25</td>
<td>Integrated testing: The challenges we now face</td>
<td></td>
<td>K. Kerr, Aberdeen Royal Infirmary - NHS Grampian, Aberdeen, GB</td>
</tr>
<tr>
<td>11:40</td>
<td>Targeted therapy and immunotherapy: Can the patient have both?</td>
<td></td>
<td>A.-M. Dingemans, Erasmus MC - University Medical Center, Rotterdam, NL</td>
</tr>
<tr>
<td>11:55</td>
<td>Co-mutations: Impact on current treatments and new combinations</td>
<td></td>
<td>P. Garrido Lopez, Hospital Universitario Ramon y Cajal, Madrid, ES</td>
</tr>
<tr>
<td>12:10</td>
<td>Rebiopsy and cfDNA in a complex and changing landscape</td>
<td></td>
<td>N. Normanno, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, Napoli, IT</td>
</tr>
<tr>
<td>12:25</td>
<td>Discussion</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Location</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
<td>------------------</td>
<td></td>
</tr>
<tr>
<td>11:15 - 12:45</td>
<td><strong>Personalised treatment of lung cancer brain metastases</strong></td>
<td>Congress Hall</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderation: J. Remon Masip¹, L. Hendriks², ¹HM CIOCC - Centro Integral Oncológico Clara Campal, Barcelona, ES, ²Maastricht University Medical Center (MUMC), Maastricht, NL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:15 - 11:30</td>
<td><strong>TKI in patients with oncogene driven NSCLC</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>J. Remon Masip, HM CIOCC - Centro Integral Oncológico Clara Campal, Barcelona, ES</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:30 - 11:40</td>
<td><strong>Case presentation: A patient with driver mutation</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>A. Levy, Gustave Roussy - Cancer Campus, Villejuif, FR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:40 - 11:55</td>
<td><strong>Immunotherapy for non-oncogene addicted NSCLC</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>L. Hendriks, Maastricht University Medical Center (MUMC), Maastricht, NL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:55 - 12:10</td>
<td><strong>Sequencing of radiotherapy and systemic therapy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>A. Levy, Gustave Roussy - Cancer Campus, Villejuif, FR</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:10 - 12:25</td>
<td><strong>When to incorporate surgery in the treatment of lung cancer brain metastases?</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>12:25 - 12:45</td>
<td><strong>Discussion</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30 - 15:00</td>
<td><strong>Janssen Oncology - Evolving treatment options and practices in EGFR-mutant NSCLC</strong></td>
<td>Forum Hall</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderation: T.B. Announced, , US</td>
<td></td>
<td></td>
</tr>
<tr>
<td>13:30 - 15:00</td>
<td><strong>AstraZeneca - CNS disease management in EGFRm NSCLC</strong></td>
<td>South Hall 2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Moderation: T.B. Announced, , US</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Speaker and Institution</td>
<td></td>
</tr>
<tr>
<td>------------</td>
<td>----------------------------------</td>
<td>------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>15:10 - 15:20</td>
<td>LBA TBC</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:20 - 15:30</td>
<td>1O - Furmonertinib versus gefitinib in treatment-naïve EGFR mutated non-small cell lung cancer: a randomized, double-blind, multi-center, phase III study (FURLONG)</td>
<td>Y. K. Shi, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center and National Clinical Research Center for Cancer and Cancer Hospital, Chinese Academy of Medical Sciences &amp; Peking Union Medical College, Beijing, CN</td>
<td></td>
</tr>
<tr>
<td>15:30 - 15:45</td>
<td>Invited Discussant of LBA TBC and 1O</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:45 - 15:55</td>
<td>Q&amp;A</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15:55 - 16:05</td>
<td>80O - Atezolizumab (atezo) vs best supportive care (BSC) in stage II-IIIA NSCLC with high PD-L1 expression: sub-analysis from the pivotal phase III IMpower010 study</td>
<td>E. Felip, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, ES</td>
<td></td>
</tr>
<tr>
<td>16:05 - 16:15</td>
<td>141O - Durvalumab (D) &amp; tremelimumab (T) + platinum-etoposide (EP) in 1L extensive-stage (ES) SCLC: characteristics of long-term survivors in the CASPIAN study</td>
<td>N. Reinmuth, Asklepios Lung Clinic, Munich-Gauting, DE</td>
<td></td>
</tr>
<tr>
<td>16:15 - 16:30</td>
<td>Invited Discussant of 80O and 141O</td>
<td></td>
<td></td>
</tr>
<tr>
<td>16:30 - 16:40</td>
<td>Q&amp;A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### 17:00 - 18:00  
**Salvage surgery and RT**  
**Congress Hall**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00</td>
<td><strong>Case presentation</strong></td>
<td>C. Le Pechoux, Institut Gustave Roussy, Villejuif, FR</td>
<td></td>
</tr>
<tr>
<td>17:15</td>
<td><strong>Surgery</strong></td>
<td>P. Van Schil, University Hospital Antwerp (UZA), Edegem, BE</td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td><strong>Radiotherapy</strong></td>
<td>D. De Ruysscher, Mastro Clinic, Maastricht, NL</td>
<td></td>
</tr>
<tr>
<td>17:45</td>
<td><strong>Discussion</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### 17:00 - 18:00  
**New TNM classification: Anatomical vs biological**  
**Forum Hall**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00</td>
<td><strong>Introduction and first vote</strong></td>
<td>V. Rusch, Memorial Sloan Kettering Cancer Center, New York, US</td>
<td></td>
</tr>
<tr>
<td>17:10</td>
<td><strong>Anatomical TNM</strong></td>
<td>R. Rami-Porta, Hospital Mutua de Terrassa, Terrassa, ES</td>
<td></td>
</tr>
<tr>
<td>17:30</td>
<td><strong>Biological TNM</strong></td>
<td>R. Osarogiagbon, Baptist Cancer Center, Memphis, US</td>
<td></td>
</tr>
<tr>
<td>17:50</td>
<td><strong>Second vote and conclusions</strong></td>
<td>V. Rusch, Memorial Sloan Kettering Cancer Center, New York, US</td>
<td></td>
</tr>
</tbody>
</table>
17:00 - 17:05  **131MO - Trends in age- and sex-specific lung cancer mortality in Europe and Northern America: analysis of vital registration data from the WHO Mortality Database between 2000 and 2017**

P. Baum, Thoraxklinik Heidelberg GmbH, Heidelberg, DE

17:05 - 17:10  **81MO - Osimertinib as neoadjuvant therapy in patients with EGFR mutated resectable stage II-IIIB lung adenocarcinoma (NEOS): Updated Results**

C. Lyu, Beijing Cancer Hospital, Beijing, CN

17:10 - 17:15  **108MO - Safety and efficacy outcomes with durvalumab after sequential chemoradiotherapy (sCRT) in Stage III, unresectable NSCLC (PACIFIC-6)**

M. Garassino, University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US

17:15 - 17:23  **Invited Discussant of 131MO, 81MO and 108MO**

L. Backhus, Stanford University, Stanford, US

17:23 - 17:28  **82MO - Risk-adjusted mortality rates as a quality proxy outperform volume in lung cancer surgery - a new perspective on hospital centralization using national population-based data**

P. Baum, Thoraxklinik Heidelberg GmbH, Heidelberg, DE

17:28 - 17:33  **109MO - Respect the Middle Lobe: Perioperative Survival of Bilobectomy Compared to Lobectomy and Pneumonectomy**

A. Li, Yale School of Medicine, New Haven, US

17:33 - 17:39  **Invited Discussant of 82MO and 109MO**

17:39 - 17:44  **157MO - Immune gene signatures for predicting pathological response of NSCLC patients treated with neoadjuvant chemoinmunotherapy**

M. Casarrubios, Instituto de Investigación Sanitaria Puerta de Hierro-Segovia de Arana, Hospital Puerta de Hierro-Majadahonda, Majadahonda, ES

17:44 - 17:49  **172MO - Analysis of comutations in DNA damage repair (DDR) related pathways with immunotherapeutic biomarkers in Chinese lung cancer patients**

J. Xu, Shandong Provincial Hospital, Shandong, CN

17:49 - 17:55  **Invited Discussant of 157MO and 172MO**

17:55 - 18:00  **Q&A**
Novartis - Management of patients with oncogene-driven NSCLC: The shift towards personalized medicine

18:15 - 19:45

Welcome and introduction
S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

18:18 - 18:38

Comprehensive biomarker testing: Understanding the person’s perspective
A.-M. Baird¹, P. Solange², ¹ Dublin, IE, ² Lausanne, CH

18:38 - 18:58

Know your options: Biomarker testing as the foundation for treatment selection
R. Büttner, Cologne, DE

18:58 - 19:13

Emerging landscape in biomarkers
N. Reguart, Hospital Clinic Barcelona, Barcelona, ES

19:13 - 19:33

Integration: How can we bring the future forward?
A. Speakers¹, S. Peters², ¹ CH, ²CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

19:33 - 19:45

Q&A with the audience & meeting closure
A. Speakers¹, S. Peters², ¹ CH, ²CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH

Thermo Fisher Scientific - Satellite Symposium

18:15 - 19:45

Moderation: T.B. Announced, , US
**01.04.2022**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Moderator/Presenter</th>
</tr>
</thead>
<tbody>
<tr>
<td>08:15 - 09:15</td>
<td><strong>Sublobar resection versus lobectomy</strong></td>
<td>Forum Hall</td>
<td>E. Lim, Royal Brompton Hospital, London, GB</td>
</tr>
<tr>
<td>08:15 - 08:25</td>
<td><strong>Introduction and first vote</strong></td>
<td></td>
<td>E. Lim, Royal Brompton Hospital, London, GB</td>
</tr>
<tr>
<td>08:25 - 08:45</td>
<td><strong>Lobectomy</strong></td>
<td></td>
<td>A. Verhagen, Radboud University Medical Center, Nijmegen, NL</td>
</tr>
<tr>
<td>08:45 - 09:05</td>
<td><strong>Sublobar</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>09:05 - 09:15</td>
<td><strong>Second vote and conclusions</strong></td>
<td></td>
<td>E. Lim, Royal Brompton Hospital, London, GB</td>
</tr>
<tr>
<td>08:15 - 09:15</td>
<td><strong>YO session 2</strong></td>
<td>South Hall 2</td>
<td>T.B. Announced, , US</td>
</tr>
<tr>
<td>08:15 - 09:15</td>
<td><strong>Mini Oral session 2</strong></td>
<td>Congress Hall</td>
<td></td>
</tr>
<tr>
<td>08:15 - 08:20</td>
<td><strong>3MO - First-line camrelizumab plus carboplatin and paclitaxel for advanced squamous non-small-cell lung cancer: Updated overall survival results from the phase 3 CameL-sq trial</strong></td>
<td></td>
<td>C. Zhou, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, CN</td>
</tr>
<tr>
<td>08:20 - 08:25</td>
<td><strong>4MO - Final Overall Survival (OS) Data of Sintilimab Plus Pemetrexed (SPP) and Platinum as First-Line (1L) Treatment for Locally Advanced or Metastatic Nonsquamous NSCLC (AMsqNSCLC) in the Phase 3 ORIENT-11 Study</strong></td>
<td></td>
<td>L. Zhang, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, CN</td>
</tr>
<tr>
<td>08:25 - 08:30</td>
<td><strong>5MO - Patient-reported outcomes (PROs) with 1L durvalumab (D), with or without tremelimumab (T), plus chemotherapy (CT) in metastatic (m) NSCLC: Results from POSEIDON</strong></td>
<td></td>
<td>E. Garon, UCLA Hematology/Oncology Santa Monica, Santa Monica, US</td>
</tr>
<tr>
<td>08:30 - 08:35</td>
<td><strong>6MO - Pembrolizumab Plus Ipilimumab or Placebo in Previously Untreated Metastatic NSCLC With PD-L1 Tumor Proportion Score &gt;50%: KEYNOTE-598 3-Year Follow-Up</strong></td>
<td></td>
<td>D. Rodriguez Abreu, Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Universidad de Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, ES</td>
</tr>
<tr>
<td>08:35 - 08:45</td>
<td><strong>Invited Discussant of 3MO, 4MO, 5MO and 6MO</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Last update: 24-02-2022 02:14:04pm
08:45 - 08:50  2MO - Final OS results and subgroup analysis of savolitinib in patients with MET exon 14 skipping mutations (METex14+) NSCLC
S. Lu, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, CN

08:50 - 08:55  7MO - Oritinib (SH-1028), a third-generation EGFR tyrosine kinase inhibitor in locally advanced or metastatic NSCLC patients with positive EGFR T790M: results of a single-arm phase II trial
C. Zhou, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai, CN

08:55 - 09:00  8MO - The efficacy and safety of TQ-B3101 monotherapy in the first line treatment in patients with ROS1 positive non-small cell lung cancer
S. Lu, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, CN

09:00 - 09:10  Invited Discussant of 2MO, 7MO and 8MO

09:10 - 09:15  Q&A

08:30 - 10:00 EONS / IASLC nurses and allied health professionals (NAHP): Committee session 1
Moderation: A. Charalambous, , CY

08:30 - 08:50  LuCE survey on living with lung cancer: Survivorship and quality of life

08:50 - 09:10  Self-management support intervention for patients and informal caregivers facing incurable cancer: A nurse-led approach

09:10 - 09:30  Novel treatments come with novel symptoms
A. O'Meara, Dublin, IE

09:30 - 09:50  A multimodal AI-based toolbox for empowering Imaging Analysis: INCISIVE project

09:50 - 10:00  Q&A / Discussion
A. Speakers, , CH

Last update: 24-02-2022 02:14:04pm
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:30 - 10:00</td>
<td><strong>Lung cancer in 2030</strong>&lt;br&gt;P. Janne, Dana Farber Cancer Institute, Boston, US</td>
</tr>
<tr>
<td>09:30 - 09:35</td>
<td>Introduction</td>
</tr>
<tr>
<td>09:35 - 10:00</td>
<td><strong>Lung cancer in 2030</strong>&lt;br&gt;P. Janne, Dana Farber Cancer Institute, Boston, US</td>
</tr>
<tr>
<td>10:30 - 12:00</td>
<td><strong>How to use real-world evidence for clinical decision making</strong>&lt;br&gt;Moderation: D. De Ruyscher¹, P. Van Schil², ¹Maastro Clinic, Maastricht, NL, ²University Hospital Antwerp (UZA), Edegem, BE</td>
</tr>
<tr>
<td>10:30 - 10:50</td>
<td><strong>Real-world data: Methodology</strong>&lt;br&gt;E. Van De Garde, UMC - University Medical Center Utrecht, Utrecht, NL</td>
</tr>
<tr>
<td>10:50 - 11:10</td>
<td><strong>Relevance of real-world data in thoracic oncology</strong>&lt;br&gt;S. Ekman, Karolinska University Hospital-Solna, Solna, SE</td>
</tr>
<tr>
<td>11:10 - 11:30</td>
<td><strong>Artificial intelligence to manage large set of data in thoracic oncology</strong>&lt;br&gt;M. Del Re, AOU Pisana - Stabilimento di Santa Chiara, Pisa, IT</td>
</tr>
<tr>
<td>11:30 - 11:50</td>
<td><strong>Deconvolution of big data sets in thoracic oncology</strong>&lt;br&gt;V. Pancaldi, IUCT - Institut Universitaire du Cancer de Toulouse - Oncopole, Toulouse, FR</td>
</tr>
<tr>
<td>11:50 - 12:00</td>
<td>Q&amp;A</td>
</tr>
</tbody>
</table>
10:30 - 12:00  New roads in I-O  Congress Hall

10:30 - 10:50  A second life for vaccines?
L. Bazhenova, Moores Cancer Center - UC San Diego Health, La Jolla, US

10:50 - 11:10  Playing with checkpoints
M. Maio, AOU Senese - Santa Maria delle Scotte, Siena, IT

11:10 - 11:30  Rethinking cytokines
E. Garon, UCLA Hematology/Oncology Santa Monica, Santa Monica, US

11:30 - 11:50  Personalizing T-cell therapies
B. Creelan, H. Lee Moffitt Cancer Center University of South Florida, Tampa, US

11:50 - 12:00  Q&A

10:30 - 12:00  Perioperative strategies: ICI, TKIs, adjuvant, neoadjuvant  Forum Hall

Moderation: E. Felip, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, ES

10:30 - 10:50  Choosing the best endpoints and surrogates for perioperative strategies in NSCLC
H. Wakelee, Stanford University, Stanford, US

10:50 - 11:10  (Neo)Adjuvant TKIs in oncogene addicted tumors
P. Forde, St James's Hospital, Dublin, IE

11:10 - 11:30  Opportunities and pitfalls of Adjuvant Immunotherapy in resected NSCLC
E. Felip, Vall d’Hebron University Hospital, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, ES

11:30 - 11:50  Opportunities and pitfalls of Neoadjuvant Immunotherapy in resectable NSCLC
T. Cascone, The University of Texas M. D. Anderson Cancer Center, Houston, US

11:50 - 12:00  Q&A
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 - 10:50</td>
<td>Psycho-support of lung cancer patients and their families at home</td>
<td></td>
</tr>
<tr>
<td>10:50 - 11:10</td>
<td>Multidisciplinary training in lung cancer professionals: The way forward</td>
<td>A. Sajnic, Zagreb, Croatia, HR</td>
</tr>
<tr>
<td>11:10 - 11:30</td>
<td>The use of non-pharmacological/complementary interventions for the management of oral toxicities in lung cancer</td>
<td></td>
</tr>
<tr>
<td>11:30 - 11:50</td>
<td>COVID-19 and the multi-disciplinary care of patients with lung cancer</td>
<td></td>
</tr>
<tr>
<td>11:50 - 12:00</td>
<td>Q&amp;A / Discussion</td>
<td>A. Speakers, CH</td>
</tr>
<tr>
<td>12:00 - 12:45</td>
<td>e-Poster Display session</td>
<td>Congress Hall</td>
</tr>
<tr>
<td>12:00 - 12:00</td>
<td>9P - Final results from TAIL: updated long-term safety and efficacy of atezolizumab (atezo) in a diverse population of patients (pts) with previously treated advanced NSCLC</td>
<td>A. Ardizzoni, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, IT</td>
</tr>
<tr>
<td>12:00 - 12:00</td>
<td>10P - Treatment-free survival (TFS) in metastatic non-small cell lung cancer (mNSCLC) patients (pts) treated with 1L nivolumab plus ipilimumab (NIVO+IPI) or platinum doublet chemotherapy (PDC) in CheckMate (CM) 227</td>
<td>S. Peters, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH</td>
</tr>
<tr>
<td>12:00 - 12:00</td>
<td>11P - Results of a phase II study investigating efutalagimod alpha (soluble LAG-3 protein) and pembrolizumab in 2nd line PD-1/PD-L1 refractory metastatic non-small cell lung carcinoma pts</td>
<td>M. Krebs, Division of Cancer Sciences, The University of Manchester and The Christie NHS Foundation Trust, Manchester, GB</td>
</tr>
<tr>
<td>12:00 - 12:00</td>
<td>12P - A phase II study of atezolizumab in combination with bevacizumab, carboplatin or cisplatin, and pemetrexed for EGFR-mutant metastatic NSCLC patients after failure of EGFR TKIs.</td>
<td>S.-G. Wu, National Taiwan University Hospital Cancer Center, Taipei City, TW</td>
</tr>
<tr>
<td>12:00 - 12:00</td>
<td>13P - Durvalumab + chemotherapy in patients (pts) with advanced EGFR mutation-positive (EGFRm) NSCLC whose disease progressed on first-line (1L)</td>
<td></td>
</tr>
</tbody>
</table>
12:00 - 12:00  **14P - Flat-dose nivolumab (NIVO) as second-line (2L) treatment (tx) in Asian patients (pts) with advanced non small cell lung cancer (NSCLC): CheckMate 870 long-term results**  
S. Lu, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, CN

12:00 - 12:00  **15P - Preliminary results of histone deacetylase inhibitor tucidinostat combined with PD-1 inhibitor sintilimab in non-small cell lung cancer failed to standard therapies**  
Y. Wang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN

12:00 - 12:00  **16P - Camrelizumab monotherapy or plus Apatinib for PD-L1-positive advanced pulmonary sarcomatoid carcinoma: A single-arm, open-label, multicenter, phase II study**  
M. Zhao, The first hospital of China medical university, Shenyang, CN

12:00 - 12:00  **17P - Safety and tolerability of sintilimab (sint) combination therapy in patients with advanced or recurrent non-small cell lung cancer (NSCLC): pooled safety analysis of ORIENT 11 and ORIENT 12 studies.**  
G. Gao, Shanghai Pulmonary Hospital, Shanghai, CN

12:00 - 12:00  **18P - RATIONALE-307: Safety analysis of patients (pts) receiving tislelizumab (TIS) plus chemotherapy (chemo) vs chemo alone in advanced squamous (sq) NSCLC**  
X. Yu, Zhejiang Cancer Hospital, Hangzhou, CN

12:00 - 12:00  **19P - Stable Disease (SD) on Amivantamab in Post-Platinum Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (Exon20ins) Mutated Non-Small Cell Lung Cancer (NSCLC): A Response-Based Analysis**  
N. Girard, Institut Curie, Institut du Thorax Curie-Montsouris, Paris, France; UVSQ, Paris Saclay Campus, Versailles, FR

12:00 - 12:00  **20P - Risk and Management of Intracranial Progression on Amivantamab in Epidermal Growth Factor Receptor (EGFR) Exon 20 insertion (ex20ins)-mutated Non-small Cell Lung Cancer (NSCLC)**  
J. Trigo, Hospital Universitario Virgen de la Victoria y Regional, IBIMA, Malaga, ES

12:00 - 12:00  **21P - Sintilimab in combination with anlotinib in non-small-cell lung cancer patients with uncommon EGFR mutations: a phase II, single-arm, prospective study**  
K. Chen, Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou, CN

12:00 - 12:00  **22P - EMB-01, an EGFR-cMET bispecific Antibody, in advanced/metastatic solid**
tumors Phase I results
Z. Qing, Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, CN

12:00 - 12:00 23P - Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: the OSIBOOST trial.
A. Veelen, Maastricht University Medical Center (MUMC), Maastricht, NL

12:00 - 12:00 24P - Tepotinib in patients with MET exon 14 skipping NSCLC: Efficacy and safety by line of therapy
F. Griesinger, Pius-Hospital, University Medicine Oldenburg, Oldenburg, DE

12:00 - 12:00 25P - Tepotinib in Asian patients with advanced NSCLC with MET exon 14 (METex14) skipping
J. Yang, National Taiwan University Hospital and National Taiwan University Cancer Center, Taipei, TW

12:00 - 12:00 26P - Capmatinib in treatment (Tx)-naive MET exon 14-mutated (METex14) advanced non-small cell lung cancer (aNSCLC): Updated results from GEOMETRY mono-1
E. Vinson, University Hospital of Cologne, Köln, DE

12:00 - 12:00 27P - Durability of Efficacy and Safety with Selpercatinib in Patients (pts) with RET Fusion+ Non-Small-Cell Lung Cancer (NSCLC)
A. Drilon, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US

12:00 - 12:00 28P - Dose determination and pharmacokinetics (PK) of pralsetinib: Results from the phase 1 ARROW study
J.F. Gainor, Massachusetts General Hospital, Boston, US

12:00 - 12:00 29P - Brigatinib (BRG) vs Crizotinib (CRZ) in Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer (NSCLC): ALTA-1L Final Results
M. Tiseo, Azienda Ospedaliero-Universitaria di Parma, Parma, IT

12:00 - 12:00 30P - A phase I, dose-escalation and dose-expansion study of SY-3505, a third-generation ALK TKI, in Chinese ALK positive advanced non-small cell lung cancer
Y.-K. Shi, Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, National Cancer Center and National Clinical Research Center for Cancer and Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN

12:00 - 12:00 31P - Efficacy and safety of utidelone in treatment-refractory advanced non-small cell lung cancer
C. Li, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, CN
12:00 - 12:00  32P - Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC - A systematic review and meta-analysis
U. Dafni, National and Kapodistrian University & Frontier Science Foundation Hellas, Athens, GR

12:00 - 12:00  33P - A literature review of Stevens-Johnson syndrome (SJS)/Toxic epidermal necrolysis (TEN) caused by Immune checkpoint inhibitors (ICIs), epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) and multikinase inhibitors (MKIs)
Z. Hu, China-Japan Friendship Hospital, Beijing, CN

12:00 - 12:00  34P - RET-MAP: An international multi-center study on clinicopathologic features and treatment response in patients with NSCLC and RET fusions
A. Marinello, Institut Gustave Roussy, Villejuif, FR

12:00 - 12:00  35P - Real-World Treatment Outcomes of Amivantamab in Pre-Approval Access (PAA) Participants with Advanced Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertion Mutations (ex20ins)
T.M. Kim, Seoul National University Hospital, Seoul, US

12:00 - 12:00  36P - Indirect Comparison of Mobocertinib Trial Data vs Real-World Data in Patients with EGFR exon 20 insertion (ex20ins)+ Non-Small Cell Lung Cancer (NSCLC)
P. Christopoulos, Thoraxklinik and National Center for Tumor Diseases at Heidelberg University Hospital; Translational Lung Research Center Heidelberg (TLRC-H), member of the German Center for Lung Research (DZL), Heidelberg, DE

12:00 - 12:00  37P - Sotorasib-induced liver and non-liver toxicity associated with sequential sotorasib following anti-PD(L)1 in KRASG12C mutant lung cancer.
A. Chour, Hôpital Louis Pradel, Hospices Civils de Lyon, Bron, FR

12:00 - 12:00  38P - The immunotherapy role in patients (pt) with KRAS mutated metastatic non-small cell lung cancer (NSCLC): differences between KRAS G12C and non-G12C.
L. Notario Rincon, ICO - Institut Català d'Oncologia Badalona, Badalona, ES

12:00 - 12:00  39P - Determination of essential biomarkers in lung cancer: a real-world data study in Spain.
V. Calvo De Juan, University Hospital Puerta de Hierro Majadahonda, Majadahonda, ES

12:00 - 12:00  40P - Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC) patients (pts): a real-world analysis
G. Pretelli, University of Padua, Padua, IT

12:00 - 12:00  41P - Progression after chemo-IO and Durvalumab in stage III Non-Small Cell Lung Cancer (NSCLC) - what should be the next line? Real-world study
12:00 - 12:00 42P - Comparative real-world analysis of pembrolizumab plus chemo vs platinum-doublet alone in metastatic non-squamous NSCLC with PD-L1 low
I. Attili, IEO - Istituto Europeo di Oncologia, Milan, IT

12:00 - 12:00 43P - Update on long term outcome of a multicentre, prospective, real-world study of camrelizumab in the Treatment of Patients with Advanced Lung Cancer
Y. Shu, Jiangsu Province People's Hospital, Nanjing, CN

12:00 - 12:00 44P - Real-world (RW) treatment patterns, patient characteristics and outcomes in advanced non-small cell lung cancer (aNSCLC) with PD1/L1 as first-line (1L) therapy in the UK and Germany
M. Snee, The Leeds Teaching Hospitals NHS Trust, Leeds, GB

12:00 - 12:00 45P - Pembrolizumab versus Best Supportive Care Survival Outcomes in ECOG Performance Status 2 NSCLC Patients
A. Elegbede, University of Calgary, Calgary, CA

12:00 - 12:00 46P - Prognostic impact of immune checkpoint inhibition in patients with metastatic non-small cell lung cancer (NSCLC): Real world study in Central Switzerland
V. Allmann, University of Basel, Basel, CH

12:00 - 12:00 47P - Real-world outcomes of immune checkpoint inhibitors and selective RET inhibitors for RET fusion non-small-cell lung cancer
R. Wan, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN

12:00 - 12:00 48P - Efficacy of osimertinib (osi) on (prevention of) bone metastases (mets) and skeletal related events (SREs) in patients (pts) with epidermal growth factor receptor mutated (EGFRm+) non-small cell lung cancer (NSCLC).
A. Brouns, Zuyderland Medical Center, Heerlen, NL

12:00 - 12:00 49P - EGFR exon 20 insertion mutations in patients with locally advanced or metastatic NSCLC in the German prospective, CRISP Registry real-world cohort (AIO-TRK-0315)
F. Griesinger, Pius-Hospital, University Medicine Oldenburg, Oldenburg, DE

12:00 - 12:00 50P - Clinical Characteristics, Treatment Patterns and Outcomes of EGFR exon 20 insertion and other EGFR mutations in Korean aNSCLC Patients
S. Yoon, Asan Medical Center - Asan Institute for Life Science, Seoul, US

12:00 - 12:00 51P - Testing Patterns and Outcomes of Different EGFR Positive Metastatic Non-Small Cell Lung Cancer (NSCLC) Patients in a Canadian Real-World Setting
D. Boyne, Oncology Outcomes Research Initiative, University of Calgary, Calgary, CA
12:00 - 12:00  **52P - ROS1 Aberrations in Non-small cell Lung Cancer Patients without Rearrangements: Clinical and molecular Characteristics**
M. Glaser, University Hospital Cologne, Köln, DE

12:00 - 12:00  **53P - Second line treatment in advanced Non Squamous (NS) Non Small Cell Lung Cancer (NSCLC) patients in Spain, analyzed in the Thoracic Tumor Registry (RTT)**
E. Carcereny Costa, ICO - Institut Català d'Oncología Badalona (Hospital Universitario Germans Trias i Pujol), Badalona, ES

12:00 - 12:00  **54P - Overall survival in patients with metastatic lung cancer from 2000 to 2020: implementation of innovative strategies in a real-world setting**
C. Basse, Institut Curie, Paris, FR

12:00 - 12:00  **55P - The Impact of Liquid Next-Generation Testing Timing on Treatment-naïve Advanced Non-small Cell Lung Cancer: A Prospective Observational Study**
C. Yang, National Taiwan University Hospital, Taipei City, TW

12:00 - 12:00  **56P - Simultaneous Tissue and Liquid Next-generation Sequencing after First-line EGFR Tyrosine Kinase Inhibitors Resistance in Advanced Non-small Cell Lung Cancer**
Y.-T. Lin, National Taiwan University Cancer Center, Taipei, TW

12:00 - 12:00  **57P - Acquired Concurrent EGFR T790M and Driver Gene resistance from EGFR-TKIs hampered osimertinib efficacy in Advanced Lung Adenocarcinoma**
F. Wu, The Second Xiangya Hospital of Central South University, Changsha, CN

12:00 - 12:00  **58P - A Predictive Model of the Diagnostic Value of Next Generation Sequencing-Based Genomics Testing in Patients with Metastatic Non-Small Cell Lung Cancer in Spain**
A. Mota, Lilly Spain, Madrid, ES

12:00 - 12:00  **59P - Clinical utility of plasma cell-free DNA EGFR mutation analysis in treatment-naïve stage IV non-small cell lung cancer patients**
B.-G. Kim, Samsung Medical Center (SMC) - Sungkyunkwan University School of Medicine, Seoul, US

12:00 - 12:00  **60P - Machine Learning Based on Blood Biomarkers Predicts Fast Progression in Advanced NSCLC Patients Treated with Immunotherapy**
J.-G. Zhou, The Second Affiliated Hospital of Zunyi Medical University, Zunyi City, CN

12:00 - 12:00  **61P - Updated efficacy and ctDNA analysis of patients with TRK fusion lung cancer treated with larotrectinib**
V. Moreno, START MADRID-FJD, Hospital Fundación Jiménez Díaz, Madrid, ES

12:00 - 12:00  **62P - Impact of the pretreatment prognostic nutritional index on the survival**
after first-line immunotherapy in non-small-cell lung cancer patients
S. Takamori, National Hospital Organization Kyushu Cancer Center, Fukuoka, JP

12:00 - 12:00
63P - Immune-related Adverse Events (irAEs) in advanced Non-small cell lung cancer (aNSCLC) patients (pts): Neutrophil to lymphocyte ratio (NLR) and the risk for toxicity recurrence
G. Pretelli, University of Padua, Padua, IT

12:00 - 12:00
64P - Clinical benefit of platinum doublet therapy for elderly patients with advanced non-small cell lung cancer: a prospective multicenter study of the national hospital organization in Japan
M. Shimokawa, Yamaguchi University Graduate School of Medicine, Ube, JP

12:00 - 12:00
65P - Blood cytokine changes in patients with advanced NSCLC receiving immunotherapy
H. Schindler, Thoraxklinik Heidelberg gGmbH, Heidelberg, DE

12:00 - 12:00
66P - Incidence and impact on survival of venous thromboembolic events in patients with advanced non-small cell lung cancer receiving Pembrolizumab as first line of treatment
P. Hulo, CHU du Nantes - Hôtel-Dieu, Nantes, Cedex, FR

12:00 - 12:00
67P - Distinct Concomitant Genetic Alterations in EGFR-Mutant Non-Small Cell Lung Cancer Patients With Brain Metastases
Y. Fan, Cancer Hospital of the University of Chinese Academy of Sciences/ Zhejiang Cancer Hospital, Hangzhou, CN

12:00 - 12:00
68P - Clinical implications of cardiotoxicity and pharmacokinetics of alectinib in patients (pts) with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)
M. Pruis, Erasmus MC Cancer Institute, Rotterdam, NL

12:00 - 12:00
69P - Tumor invasiveness, response to ALK inhibitors and resistance mechanism in NSCLC with different ALK variants
Z. Zou, Chinese Academy of Medical Sciences and Peking Union Medical College - National Cancer Center, Cancer Hospital, Beijing, CN

12:00 - 12:00
70P - Adherence to treatment recommendations from multidisciplinary tumor boards
J. Roep, Pius Hospital, Oldenburg, DE

12:00 - 12:00
71P - Predictors of anxiety and depression among advanced lung cancer patients attending palliative care department: an experience from the rural cancer centre
C. Patil, Kolhapur Cancer Centre, Kolhapur, IN

12:00 - 12:00
72P - The risk factors of developing severity in Immune Checkpoint inhibitors-related Pneumonitis in advanced lung cancer patients.
12:00 - 12:00 73P - A novel nomogram for predicting hyperprogressive disease after immune checkpoint inhibitor treatment in lung cancer
S. Cao, Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN

12:00 - 12:00 74TiP - Capmatinib plus Osimertinib vs Platinum-pemetrexed Doublet Chemotherapy as Second-line Therapy in Patients with Stage IIIB/IIIC/IV EGFR-mutant, T790M-negative, MET-amplified NSCLC
Y.-L. Wu, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, CN

12:00 - 12:00 75TiP - Open-label, Phase 2 study of tusamitamab raltansine (SAR408701) in combination with pembroizumab and with pembroizumab + platinum-based chemotherapy +/- pemetrexed in patients with CEACAM5-positive nonsquamous NSCLC (CARMEN-LC05)
L. Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, ES

12:00 - 12:00 76TiP - RMC-4630 and Sotorasib for Advanced KRASG12C NSCLC After Failure of Prior Standard Therapies: A Phase 2 Trial
M. Johnson, Sarah Cannon Research Institute at Tennessee Oncology, Nashville, US

12:00 - 12:00 77TiP - TRUST-II: A Global Phase II Study for Taletrectinib in ROS1 fusion Positive Lung Cancer and other solid tumors
M. Nagasaka, University of California Irvine School of Medicine and Chao Family Comprehensive Cancer Center, Orange, US

12:00 - 12:00 78TiP - Clinical Evaluation of NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study
B. Besse, Institut Gustave Roussy, Villejuif, FR

12:00 - 12:00 79TiP - A Phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations
F. Opdam, Department of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, NL

12:00 - 12:00 83P - Pathologic complete response (pCR) after neoadjuvant (neoadj) chemoimmunotherapy (chemo+IO) in resectable non-small cell lung cancer (NSCLC): a systematic review and pooled analysis
S. Rosner, Johns Hopkins Sidney Kimmel Cancer Center, Baltimore, US

12:00 - 12:00 84P - SHR-1316 vs placebo in combination with chemotherapy as perioperative treatment in patients with resectable stage II-III NSCLC: a randomized, double-blind, multicenter, phase 1b/3 trial
Y.-L. Wu, Guangdong Provincial People's Hospital & Guangdong Academy of Medical Sciences, Guangzhou, CN

Last update: 24-02-2022 02:14:04pm
85P - Adjuvant osimertinib in patients (pts) with stage IB-IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumour resection: ADAURA China subgroup analysis

W. Jie, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing, CN

86P - Aumolertinib as Adjuvant Therapy in Postoperative EGFR-Mutated Non-Small-Cell Lung Cancer

Q. Zhang, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, CN

87P - Patient reported Physical Function (PF) predicts long-term survival in early-stage NSCLC surgical patients

C. Pompili, University of Leeds, Leeds, GB

88P - Uncertain resection for localized cN0M0 non small cell-lung cancer: the crucial prognosis of suboptimal lymph node assessment

R. Vergé, Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR

89P - Treatment Patterns, Overall Survival (OS), and Disease-Free Survival (DFS) in Early-Stage Non-Small Cell Lung Cancer (NSCLC) Following Complete Resection

H. West, City of Hope Comprehensive Cancer Center, Duarte, US

90P - Disease-Free Survival (DFS) as a Predictor of Overall Survival (OS) in Completely Resected Early-Stage Non-Small Cell Lung Cancer (NSCLC)

H. West, City of Hope Comprehensive Cancer Center, Duarte, US

91P - Preexisting tumor host immunity delineates clinical outcomes in resectable Non-Small Cell Lung Cancer.

P. Rocha, Hospital del Mar - Parc de Salut Mar, Barcelona, ES

92P - Exploring immune dysfunction in surgically-treated early-stage NSCLC

L. Sellmer, University Hospital LMU Munich, Munich, DE

93P - Noncancer-specific mortality in patients with stage IA1 NSCLC after surgical resection: the role of comorbidities in prognosis

W. Huang, West China Hospital, Sichuan University, Chengdu, CN

94P - Preliminary outcome data for deep inspiratory breath hold guided stereotactic radiotherapy (SBRT) with robotic couch correction for early stage non small cell lung cancers (NSCLC).

T. Basu, HCG Cancer Center, Mumbai, IN

95P - Role of postoperative follow-up with 18F-FDG PET/CT in asymptomatic NSCLC patients: a retrospective single-institution study

A. Kaumanns, University Hospital Basel, Basel, CH
96P - Transbrachial Microwave Ablation - Important Role in the Battle of Lung Preservation for Multifocal Lung Primaries or Metastases  
J. Chan, The Chinese University of Hong Kong - Prince of Wales Hospital, Sha Tin, HK

97P - TNFSF14 Overexpression and poor prognosis in early stages of non-small cell lung cancer prognosis: Immunecheckpoint inhibitor databases-based study  
M. Safi, The first affiliated hospital of Dalian medical university, Dalian, CN

98P - Clinical characteristic of women under 55 years old qualified to surgical treatment of lung cancer - analysis of 1574 cases.  
A. Trojnar, Medical University of Warsaw, Warsaw, PL

99P - The value of disease-free survival (DFS) and osimertinib in adjuvant non-small cell lung cancer (NSCLC): an international Delphi consensus report  
M. Hardenberg, Charles River Associates, Cambridge, GB

100P - Physician perceptions of testing practices in patients with early and advanced stage EGFR mutation positive (EGFRm) NSCLC: A global survey  
T. Bailey, Adelphi, Macclesfield, GB

101P - Clinicopathological features and behavior of ground-glass opacity lung cancer associated with cystic airspace  
Z. Yu, State Key Laboratory of Respiratory Diseases - The First Affiliated Hospital Of Guangzhou Medical University, Guangzhou, CN

102P - Comparison of clinical characteristics and prognosis of incidentally detected and screening detected lung cancers  
S. Zo, Samsung Medical Center (SMC), Seoul, US

103P - EFFECTIVENESS OF ARTIFICIAL INTELIGENCE IN RETROSPECTIVE COVID LUNG CT ANALYSIS FOR LUNG CANCER DETECTION.  
S. Pirqulov, Clinic "Scandinavia, Saint-Petersburg, RU

104P - The potential for lung cancer detection in COVID CT scans with AI technologies usage  
S. Zinovev, Nizhny Novgorod Regional Clinical Oncology Center, Nizhny Novgorod, RU

105P - A Model of Workflow for Radiomics Signature of Stage III Non-Small Cell Lung Cancer (NSCLC) patients (pts)  
A. Ferro, Veneto Institute of Oncology IOV - IRCCS, Padova, IT

106P - Generation of synthetic ground glass opacities (GGOs) using generative adversarial networks (GANs)  
Z. Wang, Maastricht, NL
12:00 - 12:00 107P - Application of Contrast Clearance Analysis (CCA) to assess viable tumour in non-small cell lung cancer (NSCLC) brain metastases post-stereotactic radiosurgery (SRS)
S. Mohamedkhan, The Royal Marsden Hospital (Sutton), Sutton, GB

12:00 - 12:00 110P - Updated Efficacy and Safety of Entrectinib in patients (pts) with NTRK Fusion-Positive (NTRK-fp) NSCLC
B.C. Cho, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, KP

12:00 - 12:00 111P - Entrectinib in Chinese (mainland China, Hong Kong, Taiwan) patients (pts) with locally advanced/metastatic ROS1 fusion-positive (fp) NSCLC and NTRK-fp solid tumours
S. Lu, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, CN

12:00 - 12:00 112P - Patient-reported outcomes (PROs) with first-line (1L) cemiplimab in patients with locally advanced non-small cell lung cancer (laNSCLC): EMPOWER-Lung 1 subpopulation
I. Bondarenko, Dnipropetrovsk Medical Academy, Dniprop, UA

12:00 - 12:00 113P - Proton-therapy and concurrent chemotherapy in stage III NSCLC: Effects on Durvalumab eligibility and safety profile.
F. Cortiula, Maastricht University Medical Center+, Maastricht, NL

12:00 - 12:00 114P - Preliminary results of the #8220;Blue Sky Radiomics#8221; study on stage III NSCLC patients treated with chemo-radiation and consolidation immunotherapy
A. Filippi, Fondazione IRCCS Policlinico San Matteo, Pavia, IT

12:00 - 12:00 115P - Concurrent versus sequential immune checkpoint inhibition in stage III NSCLC patients treated with chemoradiation
L. Käsmann, LMU Klinikum der Universität München, Munich, DE

12:00 - 12:00 116P - Real-world outcomes with durvalumab (durva) after chemoradiotherapy (CRT) in patients with unresectable Stage III NSCLC (SPOTLIGHT)
M. Mooradian, Massachusetts General Hospital Cancer Center and Harvard Medical School, Boston, US

12:00 - 12:00 117P - Prognostic value of new grading system in resected lung adenocarcinoma after neoadjuvant therapy
H. E, Shanghai Pulmonary Hospital - Tongji University School of Medicine, Shanghai, CN

12:00 - 12:00 118P - Impact of grade ?2 pneumonitis (G2+ PNS) on patient reported outcomes (PROs) with durvalumab (D) after chemoradiotherapy (CRT) in unresectable stage III NSCLC
R. Hui, Westmead Hospital and the University of Sydney, Sydney, AU

12:00 - 12:00 119P - Evolution of the Management of Stage III Non-Small Cell Lung Cancer

Last update: 24-02-2022 02:14:04pm
(NSCLC): a Single Center Real-World Scenario over 10 years

A. Ferro, Veneto Institute of Oncology IOV - IRCCS, Padova, IT

12:00 - 12:00
120P - Efficacy of Postoperative Radiotherapy (PORT) in Stage 3A-N2 Non-Small Cell Lung Cancer: Meta-analysis of Randomized Controlled Studies

Y. Ergün, Batman Training and Research Hospital, Batman, TR

12:00 - 12:00
121P - Treatment of unresectable stage III NSCLC: real-world study and literature review

S. Verfaillie, University Hospitals Leuven - Campus Gasthuisberg, Leuven, BE

12:00 - 12:00
122P - Efficacy of Postoperative Radiotherapy (PORT) in Stage 3A-N2 Non-Small Cell Lung Cancer: Meta-analysis of Randomized Controlled Studies

12:00 - 12:00
123P - Clinical and Environment Factors Impacting Malignant Pleural Mesothelioma Prognosis

12:00 - 12:00
124P - Comparison of Survival Among Multimodality Treatment Regimens in Malignant Pleural Mesothelioma Patients in an Integrated Health System

K. Banks, University of California San Francisco- East Bay, Oakland, US

12:00 - 12:00
125P - Radiomic signature from baseline CT Scan to predict initial response to treatment in advanced/unresectable pleural mesothelioma. Preliminary data

12:00 - 12:00
126P - Characteristics and postoperative trajectory of patients requiring ICU admission following radical surgery for mesothelioma

12:00 - 12:00
127P - Does radiomics have added value in predicting the development of brain metastases in patients with radically treated stage III non-small cell lung cancer (NSCLC)?

12:00 - 12:00
128P - Surgical management of lung metastases: a work-in-progress report from an international ESTS research group

12:00 - 12:00
129P - Regulatory dendritic cells correlate with an altered T cell distribution and regulatory T cell phenotype in metastatic lymph nodes of NSCLC patients.

12:00 - 12:00
130P - Metastasis-on-chip: 3D human microvasculature network to study extravasation dynamics of lung cancer in vitro
12:00 - 12:00 132P - 20 years of real-life nationwide epidemiological data on lung cancer in non-academic French public hospitals - KBP-2020-CPHG compared to 2000 and 2010 studies.

S. Zeinali, University of Bern, Bern, CH

12:00 - 12:00 133P - Trends in incidence and mortality of lung cancer in Switzerland: possible explanations and open questions

D. Debieuvre, GHRMSA, Mulhouse, FR

12:00 - 12:00 134P - Effectiveness of Non-Pharmacologic strategies for Parental Smoking Cessation to Protect Children: A Systematic Review and Meta-analysis

D. Frisoni, HUG - Hopitaux Universitaires de Geneve, Geneva, CH

12:00 - 12:00 135P - Patterns of care and outcomes in immigrants with non-small cell lung cancer

J. Caduhada, USTH - University of Santo Tomas Hospital, valenzuela, PH

12:00 - 12:00 136P - LUNG CANCER EPIDEMIOLOGY AND SURVIVAL OUTCOMES IN VOJVODINA, SERBIA

D. Bokan, Institute for Pulmonary Diseases of Vojvodina, Sremska Kamenica, RS

12:00 - 12:00 137P - Epidemiology and histological classification of lung cancer patients in Zimbabwe: A five-year retrospective study at Parirenyatwa Radiotherapy Centre, Harare

T. Mazhindu, University of Zimbabwe, Facualty of Medicine and Health Sciences, Harare, ZW

12:00 - 12:00 138P - Prevalence and characteristics of lung cancer in families harboring pathogenic germline variants in cancer predisposing genes.

J.C. Laguna Montes, Hospital Clinic y Provincial de Barcelona, Barcelona, ES

12:00 - 12:00 139P - KRAS-G12C NSCLC linked to female sex and high risk of CNS metastasis: Real-world data from the National Swedish Lung Cancer Registry 2016-2019

J. Isaksson, Uppsala University, Uppsala, SE

12:00 - 12:00 140P - Development and Validation of Nomograms based on Clinical Characteristics and CT Reports for Preoperative Prediction of Precision Lymph Node Dissection in Lung Cancer

H. Tang, Zhongnan Hospital of Wuhan University, Wuhan, CN

12:00 - 12:00 142P - Phase IIIb study of durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CANTABRICO): treatment patterns of chemotherapy combination phase with durvalumab

D. Isla, Hospital Clinico Universitario Lozano Blesa, Zaragoza, ES

Last update: 24-02-2022 02:14:04pm
12:00 - 12:00  143P - Efficacy and Safety of the Anti-PD-L1 Monoclonal Antibody Socazolimab in Combination with Carboplatin and Etoposide for Extensive-Stage Small Cell Lung Cancer: Results from the Phase Ib Clinical Trial
S. Lu, Shanghai Lung Cancer Center, Shanghai Chest Hospital, Shanghai JiaoTong University, Shanghai, CN

12:00 - 12:00  144P - Real-world data of consolidative radiotherapy for extensive stage (ES)-SCLC treated by chemo-immunotherapy (chemo-IO)
S. Daher, Chaim Sheba Medical Center, Ramat Gan, IL

12:00 - 12:00  145P - Clinical outcomes of atezolizumab in combination with etoposide/platinum for extensive-stage small lung cancer in China: a real-world, multi-center, retrospective, controlled study
M. Zhuo, Peking University Cancer Hospital & Institute, Beijing, CN

12:00 - 12:00  146P - Impact of heart, lung and oesophageal doses on overall survival (OS) of small cell lung cancer (SCLC) patients following radical chemo-radiotherapy (RT)
B. Tahir, The University of Sheffield, Sheffield, GB

12:00 - 12:00  147P - Chemo-immunotherapy with or without consolidative radiotherapy in extensive stage small cell lung cancer: an initial report of clinical outcome and safety.
A. Bruni, University Hospital "Policlinico" of Modena, Modena, IT

12:00 - 12:00  148P - Pathological stage N1 limited-stage small-cell lung cancer patients can benefit from surgical resection
L. Yu, Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN

12:00 - 12:00  149P - Total metabolic tumor volume: a new potential prognostic factor in SCLC
E. Andrini, Department of Experimental Diagnostic and Specialized Medicine (DIMES), Alma Mater Studiorum, University of Bologna, Bologna, IT

12:00 - 12:00  150P - Monitoring of PD-L1 expression on circulating immune cells of patients with small cell-lung cancer (SCLC) receiving first-line treatment: prognostic implications
M. Papadaki, UOC - University of Crete, Heraklion, GR

12:00 - 12:00  151P - Real World Patient Eligibility for Lurbinectin/Doxorubicin in Small Cell Lung Cancer
R. Rittberg, BC Cancer, Vancouver, CA

12:00 - 12:00  152P - Immunotherapy for Extensive-Stage SCLC: Uncovering Clinical Gaps in Physician Knowledge and Practice
V. Harvey-Jones, Medscape, Global Education, London, GB

12:00 - 12:00  153P - Safety profile and associated costs of therapies for relapsed small cell

Last update: 24-02-2022 02:14:04pm
lung cancer in Switzerland
B. García San Andrés, Pharma Mar, S.A., Madrid, ES

12:00 - 12:00 154TiP - AdvanTIG-204: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus anti-PD-1 mAb tislelizumab (TIS) plus concurrent chemoradiotherapy (cCRT) in patients (pts) with untreated limited-stage small cell lung cancer (LS-SCLC)
Y. Lu, West China School of Medicine, Sichuan University, Chengdu, China; Department of Thoracic Oncology and Laboratory of Clinical Cell Therapy and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, CN

12:00 - 12:00 155TiP - Phase 2 study of tarlatamab, a half-life extended bispecific T-cell engager (HLE BiTE®) immuno-oncology therapy targeting DLL3, in third-line or later small cell lung cancer (SCLC)
S. Ramalingam, Winship Cancer Institute of Emory University, Atlanta, US

12:00 - 12:00 156TiP - An Open-Label, Single-Arm, Phase II Study Evaluating the Efficacy And Safety Of Niraparib Combined With Radiotherapy And Teriprizumab In Patients With Recurrent Small Cell Lung Cancer
W. Zeng, Zhongnan Hospital of Wuhan University, Wuhan, CN

12:00 - 12:00 158P - Real-world management of patients with EGFR exon 20-mutant NSCLC in the precision oncology era: First report from the European EXOTIC registry
G. Mountzios, Henry Dunant Hospital Centre, Athens, GR

12:00 - 12:00 159P - ReWARD Study: Real world ALK Resistance Data: A single center experience
U. Batra, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN

12:00 - 12:00 160P - LungMetrics India: Molecular epidemiology and testing patterns in 4,773 non squamous NSCLC patients
U. Batra, Rajiv Gandhi Cancer Institute and Research Centre, New Delhi, IN

12:00 - 12:00 161P - Bayesian network structure for predicting two-year survival inpatients diagnosed with non small cell lung cancer
B. Osong, Maastro, Maastricht, NL

12:00 - 12:00 162P - A CT-radiomics model to predict overall survival following curative-intent radiotherapy for stage I-III Non-Small Cell Lung Cancer
S. Hindocha, The Royal Marsden Hospital - Chelsea, London, GB

12:00 - 12:00 163P - Anti-tumor Activity of Cetuximab Plus Avelumab in Non-Small Cell Lung Cancer Patients Involves Innate Immunity Activation: Findings from the CAVE-Lung Trial
C.M. Della Corte, Università degli Studi della Campania Luigi Vanvitelli, Somma Vesuviana, IT
12:00 - 12:00 164P - Immune modulatory functions of lurbinectedin in small cell lung cancer and malignant pleural mesothelioma patients
L. Cantini, Erasmus MC Cancer Institute, Rotterdam, NL

12:00 - 12:00 165P - Dynamic evolution of blood immune-inflammatory descriptors in advanced Non Small Cell Lung Cancer undergoing first line immunotherapy-based regimens
G. Mazzaschi, University Hospital of Parma, Medical Oncology Unit, Parma, IT

12:00 - 12:00 166P - Integrated Analysis Reveals TP53 Mutation as a Biomarker of Anti-PD-1/PD-L1 Treatment for Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma Patients
S. Wang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN

12:00 - 12:00 167P - KRAS G12C lung adenocarcinoma represents a distinct group of patients with different response to immunotherapy
L. Masfarré, Hospital del Mar - Parc de Salut Mar, Barcelona, ES

12:00 - 12:00 168P - Characterization of the lung tumor microenvironment upon anti-PD-L1 therapy reveals an ambiguous role for TNF-?
K. De Ridder, Vrije Universiteit Brussel - Faculty of Medicine & Pharmacy, Brussels, BE

12:00 - 12:00 169P - Characteristics of clonal hematopoiesis (CH) in patients with non-small cell lung cancer (NSCLC): a retrospective analysis of plasma cell-free DNA (cfDNA) comprehensive genomic profiling
M. Tagliamento, Gustave Roussy, Villejuif, FR

12:00 - 12:00 170P - Clonal hematopoiesis in asymptomatic individuals enrolled in a lung cancer screening program
L. Montuenga, Clinica Universidad de Navarra, Pamplona, ES

12:00 - 12:00 171P - Detection of NTRK1/2/3 rearrangements by PCR test for 5’/3’-end unbalanced expression
E. Imyanitov, N.N. Petrov Institute of Oncology, Saint-Petersburg, RU

12:00 - 12:00 173P - Genomic characteristics and its correlations with tumor mutational burden and PD-L1 expression in Chinese lung squamous cell carcinoma
J. Xu, Shandong Provincial Hospital, Shandong, CN

12:00 - 12:00 174P - Pulmonary tuft cell-like cancers across different histotypes share molecular features with potentially druggable vulnerabilities
Y. Yamada, Kyoto University Hospital, Kyoto, JP

12:00 - 12:00 175P - Mutations and clinical significance of calcium voltage-gated channel subunit alpha 1E (CACNA1E) in non-small cell lung cancer
G. Wang, Chinese Academy of Medical Sciences and Peking Union Medical College -
12:00 - 12:00  
176P - Phase transition Early-Invasive Lung Cancer and Blood Cell Circuit  
O. Kshivets, Roshal Hospital, Roshal, RU

12:00 - 12:00  
177P - Feasibility and usefulness of evaluation of immune status of lung cancer patients by EBUS/TBNA cells analysis  
J. Domagala-Kulawik, Medical University of Warsaw, Warsaw, PL

12:00 - 12:00  
178P - Germline genetic variants associated with different premalignant lesions in the bronchial epithelium  
T. Gerashchenko, Cancer Research Institute, Tomsk National Research Medical Center, Tomsk, RU

12:00 - 12:00  
179P - Clinical profile of SMARCA4/SMARCB1-mutated Non-Small Cell Lung Carcinomas: a retrospective study in a Spanish institution  
G. Fernandez, Hospital Clinico Universitario San Carlos, Madrid, ES

12:00 - 12:00  
180P - Schwann Cells promotes tumour progression in small cell lung cancer  
S. Cao, Shanghai Chest Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, CN

12:00 - 12:00  
181P - Anlotinib enhances the antitumor activity of high-dose irradiation combined with anti-PD-L1 by potentiating the tumor immune microenvironment in murine lung cancer  
M. Yuan, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, CN

12:00 - 12:00  
182P - Therapeutic activity of thiostrepton in patient-derived malignant pleural effusions  
B. Cunniff, University of Vermont Larner College of Medicine, Burlington, US

12:00 - 12:00  
183P - Predictor Value of PD-L1 for Radiotherapy Response in Locally Advanced Non-small Cell Lung Cancer  
V. Demircan, Gazi University - Faculty of Medicine, Ankara, TR

12:00 - 12:00  
184P - Early-stage diagnosis of lung cancer with liquid biopsy test based on peripheral blood cells  
A. Thomsen, Medical Center - University of Freiburg, Freiburg, DE

12:00 - 12:00  
185P - Clinicopathological characterization of NGS detected mutations in lung cancers - a single center experience  
J. Walter, LMU Klinikum der Universität München, Munich, DE

12:00 - 12:00  
186P - CIP2A modulates PKM2 dimer-tetramer transition through
phosphorylation of serine 287 in non-small cell lung cancer

L. Liang, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Balanced, CN

12:00 - 12:00 187P - Development of a Magnetic Nanostructure for Co-delivery of Metformin and Silibinin on Growth of Lung Cancer Cells: Possible Action Through Leptin Gene and its Receptor Regulation

D. Jafari-Gharabaghlou, Hematology & Oncology Research Center - Tabriz University of Medical Sciences, Tabriz, US

12:00 - 12:00 188P - Efficacy of SARS-CoV-2 based mRNA vaccines for patients with thoracic malignancies with 6 months follow up: a prospective observational study

U. Janzic, University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, SI

12:00 - 12:00 189P - Assessment of seroconversion after SARS-CoV2 vaccination in patients with lung cancer.

I. Trontzas, Sotiria Thoracic Diseases Hospital of Athens, Athens, GR

12:00 - 12:00 190P - COVID-19 pandemic impact on lung cancer patient’s performance status and access to treatment - a comparative study pre and during COVID-19 era

R. Fernandes, Instituto Portugues de Oncologia do Porto Francisco Gentil, EPE (IPO-Porto), Porto, PT

12:00 - 12:00 191P - Lung cancer care in Europe during COVID-19: findings from a global survey of patient experience

J. Fenemore, Global Lung cancer coalition, Manchester, GB

12:00 - 12:00 192P - Randomized, phase II, placebo-controlled trial of nintedanib for the treatment of radiation pneumonitis

Z. Moore, Memorial Sloan Kettering Cancer Center, New York, US

12:00 - 12:00 193P - Safety and efficacy of immunotherapy rechallenge following a previous immune-induced interstitial lung disease

C. Joseph, Hôpital Larrey, Toulouse, FR

12:00 - 12:00 194P - Modelling strategies to combine multiple serum tumor biomarkers for early prediction of immunotherapy non-response in non-small cell lung cancer.

F. Van Delft, University of Twente, Enschede, NL

12:00 - 12:00 195P - Radiomics and dosiomics signature from whole lung predicts radiation pneumonitis: a model development study with prospective external validation and decision-curve analysis

Z. Zhang, Maastro Clinic, Maastricht, NL

12:00 - 12:00 196P - An international consensus on actions to improve lung cancer survival: a clinical review by the International Cancer Benchmarking Partnership (ICBP)

12:00 - 12:00  **197P - Lung Cancer in Lung Transplant Recipients**
M. Svorcova, Prague Lung Transplant Program, University Hospital Motol, Prague, CZ

12:00 - 12:00  **198P - Association between BTLA polymorphisms and NSCLC risk**
A. Andrzejczak, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, Wroclaw, PL

12:00 - 12:00  **199P - The Relative Impact of Surgery History on Cancer Risk**
H. Wang, State Key Laboratory of Respiratory Diseases - The First Affiliated Hospital Of Guangzhou Medical University, Guangzhou, CN

12:00 - 12:00  **200P - The value of holistic assessment and rapid intervention: The Lung Cancer Outpatient Occupational Therapy Service (LCOOTS)**
J. Welford, NUTH - Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle-upon-Tyne, GB

12:00 - 12:00  **201P - Readability of thoracic surgery consent forms in Queensland, Australia**
S. Dutta, Princess Alexandra Hospital - Metro South Health, Woolloongabba, AU

12:45 - 14:15  **Novo cure - TTFields: A potential innovative treatment modality in lung cancer**
South Hall 2
Moderation: F. Barlesi1, L. Petruzelka2, 1Gustave Roussy - Cancer Campus, Villejuif, FR, 2 , CZ

12:45 - 12:50  **Welcome & objectives**

12:50 - 13:10  **What are TTFields - Mechanism of action and experiences in solid tumors**
M. Proescholdt, UKR - University Hospital Regensburg, Regensburg, DE

13:10 - 13:30  **TTFields in malignant pleural mesothelioma (MPM) - The STELLAR trial**
G.L. Ceresoli, Humanitas Gavazzeni, Bergamo, IT

13:30 - 13:50  **TTFields: A potential innovative treatment modality in lung cancer - The LUNAR trial and beyond**
M. Cobo Dols, Biomedical Research Institute of Málaga (IBIMA), Malaga, ES

13:50 - 14:15  **Live Q&A / discussion**
A. Speakers, , CH
<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45 - 14:15</td>
<td><strong>Living with lung cancer: Meeting unmet needs (LuCE and IASLC Patient Advocacy Committee)</strong></td>
<td><strong>Moderation:</strong> D. Villalon¹, M. Hennink², ¹ Barcelona, ES, ² Groningen, NL</td>
</tr>
<tr>
<td>12:45 - 12:55</td>
<td><strong>Lung cancer needs from a psychosocial perspective: A professional’s point of view</strong></td>
<td>L.D. Csaba, Cluj-Napoca, RO</td>
</tr>
<tr>
<td>12:55 - 13:05</td>
<td><strong>Lung cancer needs from a psychosocial perspective: An advocate’s point of view</strong></td>
<td>D. Villalon, Barcelona, ES</td>
</tr>
<tr>
<td>13:05 - 13:25</td>
<td><strong>In it for the long term: Dealing with treatment effects</strong></td>
<td>M. Hennink, Groningen, NL</td>
</tr>
<tr>
<td>13:25 - 13:35</td>
<td><strong>Q&amp;A/Discussion</strong></td>
<td>A. Speakers, CH</td>
</tr>
<tr>
<td>13:55 - 14:15</td>
<td><strong>Integration of prehab and rehab in the care pathway</strong></td>
<td>H. Toghil, Swansea, GB</td>
</tr>
<tr>
<td>12:45 - 14:15</td>
<td><strong>AstraZeneca - Unresectable stage III NSCLC: No patients left behind</strong></td>
<td><strong>Forum Hall</strong></td>
</tr>
<tr>
<td></td>
<td><strong>Moderation:</strong> T.B. Announced, , US</td>
<td><strong>Congress Hall</strong></td>
</tr>
<tr>
<td>14:30 - 15:00</td>
<td><strong>Value of pathological response as an endpoint</strong></td>
<td></td>
</tr>
<tr>
<td>14:30 - 14:35</td>
<td><strong>Introduction</strong></td>
<td></td>
</tr>
<tr>
<td>14:35 - 15:00</td>
<td><strong>Value of pathological response as an endpoint</strong></td>
<td>W. Travis, New York, US</td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Venue</td>
</tr>
<tr>
<td>----------</td>
<td>-------------------------------------------------------------------------------</td>
<td>-------------------</td>
</tr>
<tr>
<td>15:10 - 16:40</td>
<td>How to tackle synchronous oligometastases</td>
<td>Forum Hall</td>
</tr>
<tr>
<td>15:10 - 15:30</td>
<td>Surveillance and detection</td>
<td></td>
</tr>
<tr>
<td>15:30 - 15:50</td>
<td>Role of surgery</td>
<td></td>
</tr>
<tr>
<td>15:50 - 16:10</td>
<td>Role of radiotherapy</td>
<td></td>
</tr>
<tr>
<td>16:10 - 16:30</td>
<td>Integrative treatment strategies and maintenance therapy</td>
<td></td>
</tr>
<tr>
<td>16:30 - 16:40</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>15:10 - 16:40</td>
<td>EGFR, Exon 20 and ALK</td>
<td>Congress Hall</td>
</tr>
<tr>
<td>15:10 - 15:30</td>
<td>Molecular mechanisms and approaches to treating resistance to first line osimertinib in EGFR-mutant lung cancer</td>
<td></td>
</tr>
<tr>
<td>15:50 - 16:10</td>
<td>Other uncommon EGFR mutations: Strategies in management</td>
<td></td>
</tr>
<tr>
<td>16:10 - 16:30</td>
<td>Updates on ALK: TKIs and beyond</td>
<td></td>
</tr>
<tr>
<td>16:30 - 16:40</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Topic</td>
<td>Speakers</td>
</tr>
<tr>
<td>--------------</td>
<td>----------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>15:10 - 15:10</td>
<td>Oligometastatic NSCLC: Who benefits the most?</td>
<td>W. Theelen, Netherlands Cancer Institute, Amsterdam, NL</td>
</tr>
<tr>
<td>15:10 - 15:10</td>
<td>Long term responders to chemotherapy / antiangiogenics</td>
<td>S. Pilotto, University of Verona, Verona, IT</td>
</tr>
<tr>
<td>15:10 - 15:30</td>
<td>Long term responders to TKIs in oncogene-addicted NSCLC</td>
<td>R. Dziadziuszko, Medical University of Gdansk, Gdansk, PL</td>
</tr>
<tr>
<td>15:30 - 15:40</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>15:40 - 16:00</td>
<td>Long term responders to immune checkpoint inhibitors</td>
<td>T. Leal, Emory University, Atlanta, US</td>
</tr>
<tr>
<td>15:10 - 16:40</td>
<td>From ‘subject’ to ‘participant’: Making person centred research a reality (LuCE and IASLC Patient Advocacy Committee)</td>
<td>A-M. Baird, Dublin, IE</td>
</tr>
<tr>
<td>15:10 - 15:30</td>
<td>Patient reported outcomes: Are they currently fit for purpose?</td>
<td>J. Galinsky, Edinburgh, GB</td>
</tr>
<tr>
<td>15:30 - 15:50</td>
<td>Lablife: Going back basics</td>
<td>A-M. Baird, Dublin, IE</td>
</tr>
<tr>
<td>15:50 - 16:00</td>
<td>Q&amp;A/#38;A / Discussion</td>
<td>A. Speakers, , CH</td>
</tr>
<tr>
<td>16:00 - 16:20</td>
<td>Translating research from bench to bedside</td>
<td>A. Curioni, Zurich, CH</td>
</tr>
<tr>
<td>16:20 - 16:40</td>
<td>Clinical trials to real world environment</td>
<td>R.A. Stahel, Bern, CH</td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Speaker(s)</td>
</tr>
<tr>
<td>-----------</td>
<td>-----------------------------------------------------------------------</td>
<td>--------------------------------------------------------------------------</td>
</tr>
<tr>
<td>17:00 - 17:20</td>
<td>Covid 19, vaccines and management of patients outside the pandemic</td>
<td><strong>Antibody-dependent immune response in cancer patients</strong>&lt;br&gt;B. Halmos, Montefiore Medical Center, New York City, US</td>
</tr>
<tr>
<td>17:20 - 17:40</td>
<td><strong>Neutralizing responses in cancer patients and variants</strong></td>
<td>M. Obeid, CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, CH</td>
</tr>
<tr>
<td>17:40 - 18:00</td>
<td><strong>COVID-19 and cancer, now and later perspectives in US</strong></td>
<td>N. Duma, Mayo Clinic, Rochester, US</td>
</tr>
<tr>
<td>18:00 - 18:20</td>
<td><strong>COVID-19 and lung cancer, management outside of the pandemic</strong></td>
<td>M. Garassino, University of Chicago Department of Medicine - Section of Hematology/Oncology, Chicago, US</td>
</tr>
<tr>
<td>18:20 - 18:30</td>
<td>Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

**Oncogene addicted tumours, KRAS, RET, HER2, BRAF**

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>17:00 - 17:20</td>
<td><strong>METex14</strong></td>
<td>L. Mezquita, Hospital Clinic y Provincial de Barcelona, Barcelona, ES</td>
</tr>
<tr>
<td>17:20 - 17:40</td>
<td><strong>New drugs targeting RET</strong></td>
<td>A. Drilon, Memorial Sloan Kettering Evelyn H. Lauder Breast Center, New York, US</td>
</tr>
<tr>
<td>17:40 - 18:00</td>
<td><strong>New drugs targeting HER2</strong></td>
<td>J. Mazieres, Centre Hospitalier Universitaire de Toulouse - Hopital Larrey, Toulouse, FR</td>
</tr>
<tr>
<td>18:00 - 18:20</td>
<td><strong>New drugs targeting BRAF</strong></td>
<td>D. Planchard, Institut Gustave Roussy, Villejuif, FR</td>
</tr>
<tr>
<td>18:20 - 18:30</td>
<td>Q&amp;A</td>
<td></td>
</tr>
<tr>
<td>Time</td>
<td>Event</td>
<td>Speaker(s)</td>
</tr>
<tr>
<td>----------</td>
<td>-----------------------------------------------------------------------</td>
<td>---------------------------------------------------------------------------</td>
</tr>
<tr>
<td>17:00 - 18:30</td>
<td><strong>Scientific advances in malignant pleural mesothelioma</strong></td>
<td><strong>Moderation:</strong> N. Reguart Aransay, Hospital Clinic y Provincial de Barcelona, Barcelona, ES</td>
</tr>
<tr>
<td>17:00 - 17:20</td>
<td><strong>Updates in the biology of malignant mesothelioma</strong></td>
<td>P. Bironzo, Azienda Ospedaliera Universitaria San Luigi Gonzaga, Orbassano, IT</td>
</tr>
<tr>
<td>17:20 - 17:40</td>
<td><strong>Surgery for malignant mesothelioma for which patient?</strong></td>
<td>I. Opitz, University Hospital Zürich, Zurich, CH</td>
</tr>
<tr>
<td>17:40 - 18:00</td>
<td><strong>Role of radical radiotherapy</strong></td>
<td>M. De Perrot, Princess Margaret Cancer Centre, Toronto, CA</td>
</tr>
<tr>
<td>18:00 - 18:20</td>
<td><strong>Systemic treatment: Where are we now and where are we heading?</strong></td>
<td>N. Reguart Aransay, Hospital Clinic y Provincial de Barcelona, Barcelona, ES</td>
</tr>
<tr>
<td>18:20 - 18:30</td>
<td><strong>Q&amp;A</strong></td>
<td></td>
</tr>
<tr>
<td>18:45 - 20:15</td>
<td><strong>MSD - Evolving immuno-oncology treatment paradigm in NSCLC</strong></td>
<td><strong>Moderation:</strong> L. Paz-Ares, Hospital Universitario 12 de Octubre, Madrid, ES</td>
</tr>
<tr>
<td>18:45 - 18:45</td>
<td><strong>Tbc</strong></td>
<td>A. Speakers, , CH</td>
</tr>
<tr>
<td>18:45 - 20:15</td>
<td><strong>Sanofi Genzyme - Quantity versus Quality of Life in Advanced NSCLC</strong></td>
<td><strong>Moderation:</strong> T.B. Announced, , US</td>
</tr>
<tr>
<td></td>
<td><strong>Patients Treated with Immunotherapy</strong></td>
<td></td>
</tr>
</tbody>
</table>
02.04.2022

08:30 - 10:00  Treatment sequencing after first-line immunotherapy
South Hall 2
Moderation: F. Cappuzzo¹, B. Besse², ¹IRCCS Istiuto Nazionale Tumori Regina Elena (IRE), Rome, IT, ²Institut Gustave Roussy, Villejuif, FR

08:30 - 08:50  Standard of care in immuno-pretreated NSCLC
M. Reck, Krankenhaus Grosshansdorf, Grosshansdorf, DE

08:50 - 09:10  Mechanisms of resistance to immunotherapy
P. Nisticò, IRCCS Istiuto Nazionale Tumori Regina Elena (IRE), Rome, IT

09:10 - 09:30  New drugs for immuno-pretreated NSCLC
M.R. García Campelo, Instituto de Investigación Biomédica de A Coruña (INIBIC), A Coruña, ES

09:30 - 09:50  Potentiality of CAR-T in lung cancer
P. Adusumilli, Memorial Sloan Kettering Cancer Center, New York, US

09:50 - 10:00  Q&A

08:30 - 10:00  AI-enabled analysis of big data for optimising cancer patient management: A glimpse to the horizon
Forum Hall
Moderation: A. Scarpa, Ospedale Universitario Verona, Verona, IT

08:30 - 08:50  Current practice and emerging breakthroughs in AI empowered pathology and genomics
A. Scarpa, Ospedale Universitario Verona, Verona, IT

08:50 - 09:10  Current practice and emerging breakthroughs in AI-imaging/radiomics
Z. Bodalal, NKI-AVL - Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Amsterdam, NL

09:10 - 09:30  Man and machine: An uneasy pair in multiparametric decision making?
N. Paragios, CentraleSupélec - Paris-Saclay campus, Gif sur Yvette, FR

09:30 - 09:50  Current practice and emerging breakthroughs in AI-enabled oncology drug development

09:50 - 10:00  Q&A
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
</table>
| 10:15 - 10:25 | **Introduction and first vote**  
S. Ramalingam, Winship Cancer Institute of Emory University, Atlanta, US |
| 10:25 - 10:45 | **Limited**  
B. Besse, Institut Gustave Roussy, Villejuif, FR |
| 10:45 - 11:05 | **Forever**  
H. Linardou, Metropolitan Hospital, Athens, GR |
| 11:05 - 11:15 | **Second vote and conclusions**  
S. Ramalingam, Winship Cancer Institute of Emory University, Atlanta, US |
| 10:15 - 10:35 | **KRAS: Finally druggable?**  
Moderation: C. Lindsay, The Christie NHS Foundation Trust, Manchester, GB |
| 10:35 - 10:55 | **RAS G12C**  
J. Menis, AOU Integrata di Verona - Ospedale Borgo Roma, Verona, IT |
| 10:55 - 11:15 | **Novel agents (RAS-ON inhibitors, siRNAs, etc.)**  
M. Awad, Dana Farber Cancer Institute, Boston, US |
| 11:15 - 11:35 | **Combination KRAS with ICI**  
A. Sacher, UHN - University Health Network - Princess Margaret Cancer Center, Toronto, CA |
| 11:35 - 11:45 | **Co-mutations**  
C. Lindsay, The Christie NHS Foundation Trust, Manchester, GB |
| 11:45 | **Q&A** |

Last update: 24-02-2022 02:14:04pm